Britta Skawran

Dr. Britta Skawran


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
RBReena Buurman
Reena Buurman
EGEngin Gürlevik
Engin Gürlevik
VSVera Schäffer
Vera Schäffer
MEMarlies Eilers
Marlies Eilers
MSMaria Sandbothe
Maria Sandbothe
BSBritta Skawran
Britta Skawran

1 May 2017 in Journal of Hepatology
Verified
Journal Article
Closed access
MSMaria Sandbothe
Maria Sandbothe
RBReena Buurman
Reena Buurman
NRNicole Reich
Nicole Reich
LGLuisa Greiwe
Luisa Greiwe
BVBeate Vajen
Beate Vajen
BSBritta Skawran
Britta Skawran

22 August 2019 in Hepatology International
Verified
Journal Article
Open access
PDF file
NHNicole Huge
Nicole Huge
MSMaria Sandbothe
Maria Sandbothe
ASAnna K. Schröder
Anna K. Schröder
ASAmelie Stalke
Amelie Stalke
MEMarlies Eilers
Marlies Eilers
BSBritta Skawran
Britta Skawran
Background Activation of Wnt/β-catenin pathway is a frequent event in hepatocellular carcinoma and is associated with enhanced cell survival and proliferation. Therefore, targeting this signaling pathway is discussed as an attractive therapeutic approach for HCC treatment. BCL9 and BCL9L, two homologous coactivators of the β-catenin transcription factor complex, have not yet been comprehensively characterized in HCC. We aimed to elucidate the roles of BCL9 and BCL9L, especially regarding Wnt/β-catenin signaling and their prognostic value in HCC. Methods Expression of BCL9/BCL9L was determined in HCC cell lines (HLE, HLF, Huh7, HepG2, Hep3B, and Huh6) and normal liver cell lines (THLE-2 and THLE-3). To analyze proliferation and apoptosis, BCL9 and/or BCL9L were knocked down in Wnt-inactive HLE and Wnt-active HepG2 and Huh6 cells using siRNA. Subsequently, Wnt reporter assays were performed in HepG2 and Huh6 cells. BCL9 and BCL9L expression, clinicopathological and survival data of public HCC datasets were analyzed, taking the Wnt signaling status into account. Results Knockdown of BCL9L, but not of BCL9, reduced Wnt signaling activity. Knockdown of BCL9 and/or BCL9L reduced cell viability and increased apoptosis of Wnt-inactive HCC cells, but had no effect in Wnt-active cells. Expression of BCL9 and BCL9L was upregulated in human HCC and increased with progressing dedifferentiation. For BCL9L, higher expression was observed in tumors of larger size. Overexpression of BCL9 and BCL9L correlated with poor overall survival, especially in HCC without activated Wnt signaling. Conclusion Oncogenic BCL9 proteins represent promising targets for cancer therapy and inhibiting them may be particularly beneficial in Wnt-inactive HCCs. Graphic abstract

1 October 2008 in Pathobiology
Verified
Journal Article
Open access
PDF file
SHSabine Hertz
Sabine Hertz
TRThomas Rothämel
Thomas Rothämel
BSBritta Skawran
Britta Skawran
CGChristian Giere
Christian Giere
DSDoris Steinemann
Doris Steinemann
LWLudwig Wilkens
Ludwig Wilkens
Objective: Chromosomal instability is a key feature in hepatocellular carcinoma (HCC). Array comparative genomic hybridization (aCGH) revealed recurring structural aberrations, whereas fluorescence in situ hybridization (FISH) indicated an increasing number of numerical aberrations in dedifferentiating HCC. Therefore, we examined whether there was a correlation between structural and numerical aberrations of chromosomal instability in HCC. Methods and Results: 27 HCC (5 well, 10 moderately, 12 lower differentiated) already cytogenetically characterized by aCGH were analyzed. FISH analysis using probes for chromosomes 1, 3, 7, 8 and 17 revealed 1.46–4.24 signals/nucleus, which correlated with the histological grade (well vs. moderately,p < 0.0003; moderately vs. lower, p < 0.004). The number of chromosomes to each other was stable with exceptions only seen for chromosome 8. Loss of 4q and 13q, respectively, were correlated with the number of aberrations detected by aCGH (p < 0.001, p < 0.005; Mann-Whitney test). Loss of 4q and gain of 8q were correlated with an increasing number of numerical aberrations detected by FISH (p < 0.020, p < 0.031). Loss of 8p was correlated with the number of structural imbalances seen in aCGH (p < 0.048), but not with the number of numerical changes seen in FISH. Conclusion: We found that losses of 4q, 8p and 13q were closely correlated with an increasing number of aberrations detected by aCGH, whereas a loss of 4q and a gain of 8q were also observed in the context of polyploidization, the cytogenetic correlate of morphological dedifferentiation.

24 June 2016 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
RBReena Buurman
Reena Buurman
MSMaria Sandbothe
Maria Sandbothe
BSBrigitte Schlegelberger
Brigitte Schlegelberger
BSBritta Skawran
Britta Skawran
Histone deacetylation, a common hallmark in malignant tumors, strongly alters the transcription of genes involved in the control of proliferation, cell survival, differentiation and genetic stability. We have previously shown that HDAC1, HDAC2, and HDAC3 (HDAC1–3) genes encoding histone deacetylases 1–3 are upregulated in primary human hepatocellular carcinoma (HCC). The aim of this study was to characterize the functional effects of HDAC1–3 downregulation and to identify functionally important target genes of histone deacetylation in HCC. Therefore, HCC cell lines were treated with the histone deacetylase inhibitor (HDACi) trichostatin A and by siRNA-knockdown of HDAC1–3. Differentially expressed mRNAs were identified after siRNA-knockdown of HDAC1–3 using mRNA expression profiling. Findings were validated after siRNA-mediated silencing of HDAC1–3 using qRTPCR and Western blotting assays. mRNA profiling identified apoptotic protease-activating factor 1 (Apaf1) to be significantly upregulated after HDAC inhibition (HLE siRNA#1/siRNA#2 p < 0.05, HLF siRNA#1/siRNA#2 p < 0.05). As a component of the apoptosome, a caspase-activating complex, Apaf1 plays a central role in the mitochondrial caspase activation pathway of apoptosis. Using annexin V, a significant increase in apoptosis could also be shown in HLE (siRNA #1 p = 0.0034) and HLF after siRNA against HDAC1–3 (Fig. 3a, b). In parallel, caspase-9 activity was increased after siRNA-knockdown of HDAC1–3 leading to enhanced apoptosis after HDAC inhibition (Fig. 3c, d). The present data show that siRNA-knockdown of HDAC1–3 plays a major role in mediating apoptotic response to HDAC inhibitors through regulation of Apaf1.

1 September 2015 in Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
Verified
Journal Article
Closed access
TRTim Ripperger
Tim Ripperger
GMGeorgi Manukjan
Georgi Manukjan
JMJohann Meyer
Johann Meyer
SWSabine Wolter
Sabine Wolter
Axel SchambachAxel Schambach
Axel Schambach
DSDoris Steinemann
Doris Steinemann